Alis Biosciences has a highly experienced and scientifically knowledgeable team to help unlock the value within residual IP.
The Alis Biosciences Leadership team is composed of independent thinkers and experts in the field, chaired by Annalisa Jenkins, and including notable figures from the pharmaceutical, biotech, banking and investing communities. The investment team has a diverse skill set, decades of relevant experience and consistent proven success in the bioscience and investment industry.
Annalisa has over 25 years of biopharma experience. She was the former global head of research and development at Merck Serono and serves on a number of public and private boards in the life sciences industry.
Nick has over 25 years of healthcare experience, covering both advisory and operational roles. Nick works with different companies and technologies which focus on identifying and developing processes to assist in improving the probability of success of drug development.
Ian is a qualified chartered accountant with over 20 years’ experience in UK listed and private equity backed businesses. Ian was most recently Head of Finance and Investor Relations at UK listed asset manager Intermediate Capital Group plc.
Martin has over 20 years’ experience in asset management and equity capital markets with Hedge Fund of Funds and US investment banks. Martin spent the last 6 years building operational experience with growing Medtech and digital health businesses where he managed big data projects and workflows.
